Current and Potential Therapies Targeting Inflammation in NASH

Key Questions

What is nonalcoholic steatohepatitis (NASH), and how is it characterized?

Nonalcoholic steatohepatitis (NASH) is the advanced form of nonalcoholic fatty liver disease (NAFLD). It is characterized by hepatic steatosis, inflammation, hepatocellular injury, and fibrosis. Inflammation plays a key role in the progression of NASH and can be provoked by intrahepatic sources such as lipotoxicity, immune responses, oxidative stress, and cell death, as well as extrahepatic sources like adipose tissue or the gut. :contentReference[oaicite:1]{index=1}

How does inflammation contribute to the progression of NASH?

Inflammation in NASH is driven by the interplay between hepatocytes, hepatic stellate cells, and recruited immune cells. This inflammatory response leads to hepatocellular injury, fibrosis, and ultimately cirrhosis, liver-related complications, end-stage liver disease, and the need for liver transplantation. :contentReference[oaicite:2]{index=2}

What are the current therapeutic strategies targeting inflammation in NASH?

Current therapeutic strategies targeting inflammation in NASH include lifestyle modifications such as weight loss and dietary changes, as well as pharmacological interventions aimed at reducing hepatic inflammation and fibrosis. These treatments aim to halt or reverse the progression of NASH and prevent complications like cirrhosis and liver cancer. :contentReference[oaicite:3]{index=3}

What potential therapies are being explored for NASH?

Potential therapies being explored for NASH include anti-inflammatory agents, antifibrotic drugs, and agents targeting specific metabolic pathways involved in the disease. These therapies aim to address the underlying mechanisms of NASH and offer hope for more effective treatments in the future. :contentReference[oaicite:4]{index=4}

Summary Video Not Available